Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology

Sector: Healthcare

Phone: 609-322-1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

shade00tree Dec. 9 at 11:59 PM

$GRCE

0 · Reply

CharlieeMungerTWITS Dec. 9 at 7:16 PM

$GRCE

0 · Reply

CharlieeMungerTWITS Dec. 9 at 11:31 AM

$GRCE 15m shares. • Public float (i.e. shares available for trading by non-insider / non-locked-up investors): ~ 8.00 million shares. Enjoy the ride !!!

0 · Reply

Drashkawisha Dec. 9 at 10:34 AM

$GRCE Volume is dry because the smart money is already seated. NDA accepted? ✅ Cash runway > 12mo? ✅ Clinical superiority (100% vs 7% bioavailability)? ✅ The move to $3.40 is just the warm-up. The real play is the PDUFA run-up starting in Jan/Feb. Don't let the low liquidity fool you. Waiting for April 23

0 · Reply

shade00tree Dec. 8 at 3:20 AM

$GRCE This. If you know you know.

0 · Reply

CharlieeMungerTWITS Dec. 8 at 12:23 AM

$GRCE STAY LONG !

0 · Reply

Drashkawisha Dec. 7 at 11:47 AM

$GRCE Quiet accumulation. Fresh position tucked away. This one is flying under the radar for now. Letting the chart develop and the story unfold. Sometimes the quiet ones pay the best. Watching closely

0 · Reply

cartman1929 Dec. 4 at 11:25 PM

$GRCE Consolidation is over. Hold, enjoy or buy more.

0 · Reply

CharlieeMungerTWITS Dec. 4 at 7:55 PM

$GRCE

0 · Reply

Drashkawisha Dec. 4 at 6:17 PM

$GRCE

0 · Reply

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 13, 2025, 8:00 AM EST - 4 weeks ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 11, 2025, 8:30 AM EST - 4 weeks ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Oct 23, 2025, 8:00 AM EDT - 7 weeks ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Sep 22, 2025, 8:00 AM EDT - 2 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 18, 2025, 8:30 AM EDT - 3 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 12, 2025, 8:00 AM EDT - 4 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jun 25, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 13, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 9 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 10 months ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 10 months ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 10 months ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 10 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 10 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 2 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 2 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 8, 2023, 9:00 AM EST - 3 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Feb 28, 2023, 1:00 PM EST - 3 years ago

Acasti Pharma Recognizes Rare Disease Day

shade00tree Dec. 9 at 11:59 PM

$GRCE

0 · Reply

CharlieeMungerTWITS Dec. 9 at 7:16 PM

$GRCE

0 · Reply

CharlieeMungerTWITS Dec. 9 at 11:31 AM

$GRCE 15m shares. • Public float (i.e. shares available for trading by non-insider / non-locked-up investors): ~ 8.00 million shares. Enjoy the ride !!!

0 · Reply

Drashkawisha Dec. 9 at 10:34 AM

0 · Reply

shade00tree Dec. 8 at 3:20 AM

$GRCE This. If you know you know.

0 · Reply

CharlieeMungerTWITS Dec. 8 at 12:23 AM

$GRCE STAY LONG !

0 · Reply

Drashkawisha Dec. 7 at 11:47 AM

0 · Reply

cartman1929 Dec. 4 at 11:25 PM

$GRCE Consolidation is over. Hold, enjoy or buy more.

0 · Reply

CharlieeMungerTWITS Dec. 4 at 7:55 PM

$GRCE

0 · Reply

Drashkawisha Dec. 4 at 6:17 PM

$GRCE

0 · Reply

RunningRobert1 Dec. 3 at 3:06 PM

$GRCE https://www.youtube.com/watch?v=qZdhpZi_mes Please join me for a Live Stream today were we will be looking at the best microcap stocks for 2026. If you see this it is because your stock is in the top

1 · Reply

Drashkawisha Dec. 2 at 12:40 PM

$GRCE The fear of the $3.40 warrant overhang is misunderstood. Institutions aren't selling there because they lack conviction on the April PDUFA. They are selling to de-risk and secure a "Free Ride" on house money. Let them feed the liquidity. Cash runway Clinical differentiation PDUFA April 2026 Once we chew through the $3.40 supply, the real gap up begins.

0 · Reply

Drashkawisha Dec. 1 at 7:19 AM

$GRCE Bullish on the GTx-104 data and the unmet need in the ICU. The clinical case is strong. However, looking at the Q3 filings - cash runway seems tight (<12 months) with the "going concern" note. For those tracking closely: Do you expect them to bridge the gap to the April PDUFA with the ATM facility, or are you modeling in a direct offering/dilution event before the approval? Trying to time my entry properly

1 · Reply

JujuInvestor2013 Nov. 30 at 1:46 PM

$GRCE waiting since 6 months - 62k in because i truly think that it may x3 / x5 untill april 2026, very small float, lot of green signals, just being patient before take off 🚀🚀🚀🙏

1 · Reply

CharlieeMungerTWITS Nov. 27 at 11:23 AM

$GRCE wowza $6 by March

0 · Reply

jjangles123 Nov. 26 at 8:16 PM

$GRCE I’m in with a small position. What do we see from now until April?

1 · Reply

CharlieeMungerTWITS Nov. 24 at 12:22 AM

$GRCE I’m ready for you!

0 · Reply

CharlieeMungerTWITS Nov. 21 at 2:57 PM

$GRCE

0 · Reply

jjangles123 Nov. 18 at 6:49 PM

$GRCE seems pretty stable, pdufa end of April? Cash runway until Q3 ‘26? Can anyone enlighten me on getting in now?

1 · Reply

RunningRobert1 Nov. 17 at 2:20 PM

$GRCE Grace Therapeutics GRCE 3Q 2025 Summary 17Nov2025 https://youtu.be/V_d2m8gsY1k PDUFA is less then 2 quarters (23Apr2026) overall I would expect some run up going in next year, and then we will safety withdraw the original investment, and then free-rolling into the PDUFA

1 · Reply

Mikshagav Nov. 14 at 12:39 PM

$GRCE added more please don’t disappoint me🥹

0 · Reply

BB_88_ Nov. 14 at 12:54 AM

$GRCE Q1 they will run it

0 · Reply

Market Cap	51.22M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	86,600
Avg Vol	64,142
Day's Range	N/A - N/A
Shares Out	15.47M
Stochastic %K	50%
Beta	0.59
Analysts	Strong Sell
Price Target	$11.83